inhibitory and supra-inhibitory concentrations of levofloxacin on the growth of surviving L. pneumophila in human mononuclear cells. These observations are compared with the effects of erythromycin and rifampicin, used singly and in combination.
Materials and methods

Legionella pneumophila
L. pneumophila L-1033, serogroup I, isolated from the sputum of a patient with pneumonia was obtained from the Wadsworth Center for Research, New York State Department of Health, Albany, NY. The isolate was kept frozen in skim milk at 70°C until the experiment, then subcultured on buffered charcoal yeast extract (BCYE) agar, supplemented with 5% -ketoglutarate, and incubated at 35°C in 5% CO 2 . Colonies from the 48 h subculture were removed before each experiment, inoculated into BYE broth and incubated for 18 h at 35°C in a shaking water bath. Bacteria were then diluted to 10 6 cfu/mL in BYE broth for incubation with antibiotics or kept in broth (control) until their addition to phagocytic cells.
Human mononuclear phagocytes (HMN)
HMN were separated from heparinized venous blood obtained from normal volunteers using Histopaque-1077 (Sigma, Cincinnati, OH, USA). By trypan blue testing the viability of HMN was 95%. HMN were suspended in RPMI 1640 medium with 10% fetal calf serum (2 10 6 HMN/mL). They were added to the wells of 24-well flatbottom tissue culture plates (Corning, Belleville, NY, USA) and incubated for 2 h at 35°C in 5% CO 2 to allow adhesion. Adhesion was 90% in each well before the addition of L. pneumophila.
Opsonin
Pooled heat inactivated normal human serum diluted to 20% (v/v) in RPMI 1640 was used to opsonize L. pneumophila at 35°C for 1 h.
Antibiotics
Levofloxacin was a gift of the Pharmaceutical Research Institute, Robert Wood Johnson Corp. (Princeton, NJ); erythromycin and rifampicin were obtained from Sigma. All antibiotic solutions were made fresh for each experiment according to the supplier's instructions. Using the macrodilution technique, the MIC (in mg/L) of each drug was determined in BYE broth. 5 The MIC for L. pneumophila L-1033 was 0.03, 0.5 and 0.001 mg/L of levofloxacin, erythromycin, and rifampicin, respectively. 
Statistical analysis and reporting of results
For test assays where L. pneumophila were undetectable at day 0, but subsequently were detected in wells, we assigned the number 25 cfu/mL. The minimal sensitivity of our assay in detecting L. pneumophila was 50 cfu/mL so that the true observed count, undetectable, was between 1 and 49 cfu/mL. Under control conditions (i.e. no antibiotic), during the 3 days of the experiment, counts of L. pneumophila (cfu/mL) increased to a peak and then declined. In each assay, the peak log 10 count was estimated by fitting a third-degree polynomial to the observed log 10 counts using the method of least squares. 6 The estimated maximum log 10 count, based upon 13 assays, was 5.91 with a standard error of 0.12. On the average, the peak count occurred at day 0.9 (S.E. 0.1). Statistical analysis utilized the analysis of variance technique 7 and was done on the difference between the observed log 10 (cfu/mL) and the estimated maximum log 10 (cfu/mL) under control conditions. Results expressed, at each time point sampled (days 0, 1, 2, 3), the observed colony counts as a percentage of the estimated maximum control count. The level of significance was 0.05. Figure 1 demonstrates the effect of pretreatment of L. pneumophila with 1 , 2 and 4 MIC of levofloxacin and its capacity to regrow on days 1, 2 and 3. At day 0, eight of 12 assays showed that the number of viable bacteria was below the detectable threshold of 50 cfu/mL. Beyond day 0, all three doses of levofloxacin caused concentration-dependent different suppression of regrowth (P 0.01). By day 3, regrowth of L. pneumophila was lowest at 4 MIC of levofloxacin compared with pretreated L. pneumophila with the control and 1 or 2 MIC (P 0.05). Figure 2 demonstrates the effect of pretreatment of L. pneumophila with 1 , 2 and 4 MIC of rifampicin and regrowth of the organism on days 1, 2 and 3. Eleven of 12 assays at day 0 demonstrated the marked effect of the drug by the absence of detectable viable bacteria ( 50 cfu/mL). Regrowth of L. pneumophila pretreated with rifampicin at 1 MIC was higher than that of L. pneumophila pretreated with 2 or 4 MIC over the 3-day period (P 0.01). After day 1, the greater rate of regrowth of the micro-organism pretreated with 4 MIC of rifampicin was observed in all assays. Peak regrowth time was not determined, as the assay was terminated at day 3. Figure 3 demonstrates the effects of pretreatment of L. pneumophila with 1 , 2 and 4 MIC concentrations of erythromycin and regrowth of the organism on days 1, 2 and 3. All concentrations of erythromycin reduced the day 0 inoculum, but the effect of 2 and 4 MIC drug concentrations was greater than the effect of 1 MIC (P 0.01). Pretreatment with 1 MIC reduced and delayed peak regrowth to 30% of the maximum control growth (P 0.05). of the inoculum before exposure to the mononuclear cells. However, at day 1 the percent average count was greater for erythromycin-pretreated organisms than for either levofloxacin-or rifampicin-pretreated L. pneumophila (P 0.05). Organisms pretreated with 4 MIC of rifampicin demonstrated the most rapid rate of regrowth compared with erythromycin or levofloxacin. By day 3, L. pneumophila pretreated with levofloxacin had the least regrowth compared with erythromycin or rifampicin (P 0.01). All three drugs decreased the counts of cfu/mL below the maximum estimated control peak by day 3, with levofloxacin at 1.7%, compared with 18% and 24.5% for rifampicin and erythromycin, respectively.
Results
Combinations of levofloxacin rifampicin, levofloxacin erythromycin and erythromycin rifampicin were tested by pretreating L. pneumophila at 1 MIC of each drug. A comparison of these combinations was made with the results of single drugs. There were no added or interfering effects of the drugs used in combination (data not shown).
Pretreatment of L. pneumophila with low concentrations of levofloxacin, rifampicin and erythromycin (1/512 to 1 MIC) for short time periods (20-180 min) had no effect on the regrowth of the organism (data not shown).
Discussion
Our data demonstrate a decrease in both the rate and the degree of intracellular regrowth of L. pneumophila previously treated with clinically achievable concentrations of levofloxacin, rifampicin or erythromycin. The decrease and the delay in regrowth of L. pneumophila on day 3 was most evident after pretreatment with levofloxacin at 4 MIC for 18 h (P 0.01). Sub-MIC concentrations of antibiotics for shorter time periods were ineffective. Furthermore, there was no evidence of additive or synergic effect when antibiotic combinations were studied at 1 MIC concentrations.
Several mechanisms that explain the effect of antibiotic pretreatment of L. pneumophila interaction with human monocytes are possible. They include post-antibiotic leucocyte enhancement effect (enhanced phagocytosis and/or enhanced intracellular killing of L. pneumophila), or prolonged growth inhibition by antibiotics (postantibiotic effect) on intracellular L. pneumophila. 8 Enhancement of phagocyte-bacterial interaction as an antimicrobial effect against other micro-organisms has been described and is known to occur even with subinhibitory concentrations of antimicrobials.
1,9-16 Changes in bacterial morphology or external surface characteristics such as hydrophobicity or expression of opsonic binding sites have been suggested as mechanisms for increased phagocytosis of antibiotic-pretreated bacteria. 1, 14 In the present study, we did not perform direct measurements of phagocytosis of pretreated L. pneumophila. We studied the net regrowth of cell-associated bacteria. Although enhanced intracellular killing of pretreated bacteria is a possible mechanism for the delayed and decreased intracellular regrowth of L. pneumophila, it is known that human monocytes and macrophages in vitro 2 and ex vivo 17 lack the capacity to kill ingested L. pneumophila as opposed to other Gram-negative bacilli. A likely explanation for the observations reported is a residual (post-antibiotic) effect of the antimicrobials used in the pretreatment of L. pneumophila. Only one previous report describes a slight effect of quinolone pretreatment with subinhibitory (0.25 MIC) concentrations on intracellular regrowth of L. pneumophila. 18 In vitro and in the absence of monocytes, the fluoroquinolone antibiotics lomefloxacin and ciprofloxacin have demonstrated a postantibiotic effect against L. pneumophila grown in BYE broth. The duration of this effect was 3.2 h for ciprofloxacin to 5.3 h for lomefloxacin, after a 1 h incubation at 4 MIC of the test strain. 19 The post-antibiotic effect on L. pneumophila in phagocytes after incubation of ingested bacteria exposed to quinolones, macrolides and rifampicin has also been studied. [20] [21] [22] [23] It is known that fluoroquinolones are rapidly taken up and dissipated from both infected and noninfected phagocytes after the ambient antibiotic is removed. 24 It is likely, therefore, that the suppression of regrowth observed intracellularly in our study was a result of the post-antibiotic effect on L. pneumophila. Minimal enhancement of intracellular killing of L. pneumophila by the phagocytes cannot be excluded. The significance of our findings can be inferred from the understanding of the early events in the cellular pathogenesis of legionellosis. Although airway macrophages and monocytes subsequently recruited from the circulation phagocytose L. pneumophila, this micro-organism is not killed effectively. Replication is followed by extracellular spread and invasion of other phagocytes, in which conditions for multiplication are excellent. 25 Exposure of L. pneumophila to antimicrobials which act on both extracellular as well as intracellular organisms during infection should, therefore, be beneficial. In the case of fluoroquinolones, including levofloxacin, a prolonged postantibiotic effect could be anticipated on bacteria exposed before the ingestion by phagocytes, allowing a better possibility for phagocytic cells to achieve increased bactericidal capability. Rifampicin has been demonstrated to decrease the post-antibiotic effect of fluoroquinolones against Gram-negative bacilli 26 and should be evaluated carefully in a similar test system against intracellular and extracellular L. pneumophila. 3, 27 Less activity would be anticipated from erythromycin, with a post-antibiotic effect of 30 min. 19 In conclusion, pretreatment of L. pneumophila with levofloxacin at clinically achievable concentrations affects the rate and degree of regrowth of L. pneumophila ingested by human monocytes. A lesser effect is seen with rifampicin. Erythromycin is relatively ineffective at delaying the intracellular regrowth of pretreated L. pneumophila. Therefore, levofloxacin may have advantages in the treatment of legionellosis and should be evaluated in clinical studies.
